Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

PMG Research Inc

Neither a doctor nor a teaching hospital

Research payments

$27,491,594

6,042 payments

Through program year 2025, PMG Research Inc is reported as receiving $27,491,594 in research payments, across 6,042 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $51,133 20
2024 Research $225,041 33
2023 Research $1,549,180 252
2022 Research $4,042,365 1,349
2021 Research $9,131,093 1,526
2020 Research $4,189,613 1,145
2019 Research $8,303,169 1,717

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $9,186,618 1,615 payments
  2. Regeneron Pharmaceuticals, Inc. $4,405,766 843 payments
  3. GlaxoSmithKline, LLC. $3,523,893 1,485 payments
  4. Novo Nordisk AS $2,550,986 275 payments
  5. AbbVie, Inc. $1,794,126 615 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $911,193 40 payments
  7. BioNTech SE $777,011 102 payments
  8. AstraZeneca Pharmaceuticals LP $688,642 66 payments
  9. Sanofi US Services Inc. $471,107 90 payments
  10. Kowa Research Institute, Inc. $394,978 191 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $5,278,317 448 payments
  2. A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $1,706,005 210 payments
  3. A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $1,546,158 766 payments
  4. Study name not reported $1,351,429 339 payments
  5. A 26Week Phase 2B 2Part Randomized Doubleblind Placebo Controlled Parallel Group Doseranging Study to Evaluate the Efficacy and Safety of Pf06882961 Administration in Adults With Obesity $1,321,778 192 payments
  6. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $1,035,487 527 payments
  7. Pre-commercial $777,011 102 payments
  8. Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Nsaid Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $657,433 44 payments
  9. Nn9536-4375 $656,434 59 payments
  10. M16-100 $648,127 171 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $786,011 103 payments
  2. Other $210,629 38 payments
  3. Professional salary support $16,178 8 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record